25 XP   0   0   10

Cumberland Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Cumberland Pharmaceuticals Inc together

PenkeI guess you are interested in Cumberland Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cumberland Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cumberland Pharmaceuticals Inc

I send you an email if I find something interesting about Cumberland Pharmaceuticals Inc.

Quick analysis of Cumberland Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Cumberland Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$2.06
Expected worth in 1 year
$1.63
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.43
Return On Investment
-24.2%

For what price can you sell your share?

Current Price per Share
$1.79
Expected price per share
$1.6 - $2.1
How sure are you?
50%

1. Valuation of Cumberland Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.79

Intrinsic Value Per Share

$2.39 - $9.38

Total Value Per Share

$4.45 - $11.44

2. Growth of Cumberland Pharmaceuticals Inc (5 min.)




Is Cumberland Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$29.2m$38.6m-$4.1m-12.1%

How much money is Cumberland Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$1.4m-$156.4k-10.0%
Net Profit Margin-16.9%-14.1%--

How much money comes from the company's main activities?

3. Financial Health of Cumberland Pharmaceuticals Inc (5 min.)




What can you expect buying and holding a share of Cumberland Pharmaceuticals Inc? (5 min.)

Welcome investor! Cumberland Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Cumberland Pharmaceuticals Inc.

What can you expect buying and holding a share of Cumberland Pharmaceuticals Inc?

First you should know what it really means to hold a share of Cumberland Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Cumberland Pharmaceuticals Inc is $1.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cumberland Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cumberland Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.06. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cumberland Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.44-24.8%-0.10-5.6%-0.10-5.3%-0.07-4.1%-0.06-3.2%
Usd Book Value Change Per Share-0.43-24.2%-0.11-6.1%-0.10-5.3%-0.08-4.2%-0.06-3.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.021.1%
Usd Total Gains Per Share-0.43-24.2%-0.11-6.1%-0.10-5.3%-0.08-4.2%-0.04-2.2%
Usd Price Per Share1.79-1.78-2.39-3.31-4.59-
Price to Earnings Ratio-1.01-1.71--9.46--21.07-8.25-
Price-to-Total Gains Ratio-4.13--27.13--73.43--104.14--54.44-
Price to Book Ratio0.87-0.75-0.90-1.10-1.23-
Price-to-Total Gains Ratio-4.13--27.13--73.43--104.14--54.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.79
Number of shares558
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.11-0.08
Usd Total Gains Per Share-0.11-0.08
Gains per Quarter (558 shares)-60.54-42.30
Gains per Year (558 shares)-242.16-169.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-242-2520-169-179
20-484-4940-338-348
30-726-7360-508-517
40-969-9780-677-686
50-1211-12200-846-855
60-1453-14620-1015-1024
70-1695-17040-1184-1193
80-1937-19460-1354-1362
90-2179-21880-1523-1531
100-2422-24300-1692-1700

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%4.08.00.033.3%4.016.00.020.0%13.027.00.032.5%41.031.00.056.9%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%9.031.00.022.5%33.036.03.045.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.071.01.4%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%10.030.00.025.0%34.035.03.047.2%

Fundamentals of Cumberland Pharmaceuticals Inc

About Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Fundamental data was last updated by Penke on 2024-03-20 14:05:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Cumberland Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cumberland Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -67.3% means that $-0.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is -67.3%. The company is making a huge loss. -2
  • The TTM is -16.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-67.3%TTM-16.9%-50.4%
TTM-16.9%YOY-14.1%-2.8%
TTM-16.9%5Y-11.8%-5.1%
5Y-11.8%10Y-9.2%-2.6%
1.1.2. Return on Assets

Shows how efficient Cumberland Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -7.7% Return on Assets means that Cumberland Pharmaceuticals Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is -7.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.7%TTM-1.9%-5.8%
TTM-1.9%YOY-1.5%-0.4%
TTM-1.9%5Y-1.2%-0.7%
5Y-1.2%10Y-1.0%-0.3%
1.1.3. Return on Equity

Shows how efficient Cumberland Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -21.3% Return on Equity means Cumberland Pharmaceuticals Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is -21.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.3%TTM-5.3%-15.9%
TTM-5.3%YOY-3.7%-1.6%
TTM-5.3%5Y-2.9%-2.4%
5Y-2.9%10Y-2.0%-0.9%

1.2. Operating Efficiency of Cumberland Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cumberland Pharmaceuticals Inc is operating .

  • Measures how much profit Cumberland Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -22.3% means the company generated $-0.22  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is -22.3%. The company is operating very inefficient. -2
  • The TTM is -6.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-22.3%TTM-6.5%-15.8%
TTM-6.5%YOY-14.2%+7.6%
TTM-6.5%5Y-12.3%+5.8%
5Y-12.3%10Y-7.8%-4.5%
1.2.2. Operating Ratio

Measures how efficient Cumberland Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are $1.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is 1.223. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.143. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.223TTM1.143+0.080
TTM1.143YOY1.142+0.001
TTM1.1435Y1.153-0.010
5Y1.15310Y1.097+0.056

1.3. Liquidity of Cumberland Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cumberland Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.28 means the company has $1.28 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is 1.276. The company is just able to pay all its short-term debts.
  • The TTM is 1.532. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.276TTM1.532-0.256
TTM1.532YOY1.786-0.254
TTM1.5325Y2.004-0.472
5Y2.00410Y3.531-1.527
1.3.2. Quick Ratio

Measures if Cumberland Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.00 means the company can pay off $1.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is 1.003. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.119. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.003TTM1.119-0.115
TTM1.119YOY1.271-0.152
TTM1.1195Y1.526-0.407
5Y1.52610Y3.430-1.904

1.4. Solvency of Cumberland Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cumberland Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cumberland Pharmaceuticals Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.64 means that Cumberland Pharmaceuticals Inc assets are financed with 64.2% credit (debt) and the remaining percentage (100% - 64.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is 0.642. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.605. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.642TTM0.605+0.037
TTM0.605YOY0.587+0.019
TTM0.6055Y0.536+0.069
5Y0.53610Y0.380+0.157
1.4.2. Debt to Equity Ratio

Measures if Cumberland Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 177.4% means that company has $1.77 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cumberland Pharmaceuticals Inc:

  • The MRQ is 1.774. The company is just able to pay all its debts with equity.
  • The TTM is 1.526. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.774TTM1.526+0.248
TTM1.526YOY1.412+0.114
TTM1.5265Y1.180+0.346
5Y1.18010Y0.745+0.434

2. Market Valuation of Cumberland Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cumberland Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Cumberland Pharmaceuticals Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.01 means the investor is paying $-1.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cumberland Pharmaceuticals Inc:

  • The EOD is -1.008. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.009. Based on the earnings, the company is expensive. -2
  • The TTM is 1.712. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-1.008MRQ-1.009+0.001
MRQ-1.009TTM1.712-2.721
TTM1.712YOY-9.462+11.174
TTM1.7125Y-21.072+22.784
5Y-21.07210Y8.252-29.324
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cumberland Pharmaceuticals Inc:

  • The EOD is 6.654. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 6.660. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 2.286. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD6.654MRQ6.660-0.006
MRQ6.660TTM2.286+4.374
TTM2.286YOY-10.660+12.946
TTM2.2865Y1.293+0.994
5Y1.29310Y-5.436+6.729
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cumberland Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Cumberland Pharmaceuticals Inc:

  • The EOD is 0.867. Based on the equity, the company is cheap. +2
  • The MRQ is 0.868. Based on the equity, the company is cheap. +2
  • The TTM is 0.749. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.867MRQ0.868-0.001
MRQ0.868TTM0.749+0.119
TTM0.749YOY0.900-0.151
TTM0.7495Y1.096-0.347
5Y1.09610Y1.235-0.139
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cumberland Pharmaceuticals Inc.

3.1. Institutions holding Cumberland Pharmaceuticals Inc

Institutions are holding 15.654% of the shares of Cumberland Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Renaissance Technologies Corp3.89370.0015549863-5900-1.0616
2023-12-31Vanguard Group Inc2.6502037425111250.3015
2023-12-31Dimensional Fund Advisors, Inc.2.59130.0002365934-13786-3.6306
2023-12-31Bridgeway Capital Management, LLC2.02990.010728665500
2023-12-31Acadian Asset Management LLC1.33240.001318816400
2023-12-31BlackRock Inc0.7859011099000
2023-12-31Geode Capital Management, LLC0.603808527400
2023-12-31Bank of New York Mellon Corp0.53307526800
2023-12-31State Street Corporation0.281803979000
2023-12-31Two Sigma Investments LLC0.23390.000133030-200-0.6019
2023-12-31Two Sigma Advisers, LLC0.16570.000123400-200-0.8475
2023-12-31Northern Trust Corp0.1288018189-1635-8.2476
2023-12-31Cresset Asset Management, LLC0.08520.00011202510009.0703
2023-12-31Morgan Stanley - Brokerage Accounts0.079801127400
2023-12-31Wiley Bros.-Aintree Capital, LLC0.07790.004811000110000
2023-09-30Citadel Advisors Llc0.04205933-13776-69.897
2023-12-31Tower Research Capital LLC0.03990.0001562859611.8442
2023-12-31Oakworth Capital Inc0.02160.0004305200
2023-12-31SIMPLEX TRADING, LLC0.001702372370
2023-12-31Royal Bank of Canada0.0010138-10-6.7568
Total 15.57950.01932200095-21549-1.0%

3.2. Funds holding Cumberland Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.8841028082000
2023-12-31Bridgeway Ultra-Small Company1.56370.467923306800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.56520.00028424400
2024-01-31DFA US Targeted Value I0.53490.00137972000
2023-12-31Bridgeway Ultra-Small Company Market0.33470.04674988700
2024-01-31DFA US Micro Cap I0.32050.00154777200
2024-02-29Dimensional US Targeted Value ETF0.31080.0014632700
2024-01-31Fidelity Extended Market Index0.28470.00034243600
2024-01-31DFA US Core Equity 2 I0.20650.00023077100
2024-01-31DFA US Vector Equity I0.1580.00112354800
2024-02-29Dimensional US Marketwide Value ETF0.15650.00052331900
2024-01-31DFA US Core Equity 1 I0.15020.00022238100
2024-01-31Fidelity Series Total Market Index0.14810.00012208100
2024-02-29Dimensional US Small Cap ETF0.12550.00051869900
2024-01-31Dimensional Global Trgtd Value USD Acc0.09760.00061454800
2024-01-31Fidelity Nasdaq Composite Index0.0760.00021132700
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06860.00031023100
2024-02-29Vanguard Balanced Index Inv0.06160918700
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05510.00038217150.1829
2023-12-31SSgA U.S. Extended Market Index Class I0.04090.0004609000
Total 7.14320.52331064673+15+0.0%

3.3. Insider Transactions

Insiders are holding 45.148% of the shares of Cumberland Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-12-21James JonesBUY882.22
2022-12-19Caroline YoungBUY302.21
2022-12-16Caroline YoungBUY202.22
2022-12-14Caroline YoungBUY202.21
2022-12-12Caroline YoungBUY202.14
2022-12-09Caroline YoungBUY202.15
2022-12-07Caroline YoungBUY202.18
2022-12-05Caroline YoungBUY202.19
2022-12-01Caroline YoungBUY202.33
2022-11-28Caroline YoungBUY202.37
2022-11-25Caroline YoungBUY202.31
2022-11-23Caroline YoungBUY202.29
2022-11-21Caroline YoungBUY202.38
2022-11-18Caroline YoungBUY202.27
2022-11-16Caroline YoungBUY202.31
2022-11-14Caroline YoungBUY202.32
2022-11-11Caroline YoungBUY202.32
2022-11-09Caroline YoungBUY202.37
2022-11-07Caroline YoungBUY202.45
2022-11-04Caroline YoungBUY202.42

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cumberland Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.433-0.108-75%-0.095-78%-0.076-83%-0.058-87%
Book Value Per Share--2.0642.391-14%2.651-22%2.936-30%3.624-43%
Current Ratio--1.2761.532-17%1.786-29%2.004-36%3.531-64%
Debt To Asset Ratio--0.6420.605+6%0.587+9%0.536+20%0.380+69%
Debt To Equity Ratio--1.7741.526+16%1.412+26%1.180+50%0.745+138%
Dividend Per Share----0%-0%-0%0.019-100%
Eps---0.444-0.099-78%-0.096-78%-0.073-83%-0.057-87%
Free Cash Flow Per Share--0.0670.098-31%0.110-39%0.079-15%0.041+62%
Free Cash Flow To Equity Per Share---0.038-0.031-19%0.073-151%-0.006-85%0.002-1905%
Gross Profit Margin--1.757-4.584+361%5.429-68%5.019-65%1.122+57%
Intrinsic Value_10Y_max--9.376--------
Intrinsic Value_10Y_min--2.389--------
Intrinsic Value_1Y_max--0.487--------
Intrinsic Value_1Y_min--0.179--------
Intrinsic Value_3Y_max--1.808--------
Intrinsic Value_3Y_min--0.594--------
Intrinsic Value_5Y_max--3.545--------
Intrinsic Value_5Y_min--1.066--------
Market Cap25375935.0000%25400035.05025556264.948-1%34800742.179-27%50030147.386-49%73371935.069-65%
Net Profit Margin---0.673-0.169-75%-0.141-79%-0.118-82%-0.092-86%
Operating Margin---0.223-0.065-71%-0.142-37%-0.123-45%-0.078-65%
Operating Ratio--1.2231.143+7%1.142+7%1.153+6%1.097+12%
Pb Ratio0.8670%0.8680.749+16%0.900-4%1.096-21%1.235-30%
Pe Ratio-1.008+0%-1.0091.712-159%-9.462+837%-21.072+1988%8.252-112%
Price Per Share1.7900%1.7921.775+1%2.389-25%3.313-46%4.586-61%
Price To Free Cash Flow Ratio6.6540%6.6602.286+191%-10.660+260%1.293+415%-5.436+182%
Price To Total Gains Ratio-4.130+0%-4.134-27.125+556%-73.429+1676%-104.137+2419%-54.443+1217%
Quick Ratio--1.0031.119-10%1.271-21%1.526-34%3.430-71%
Return On Assets---0.077-0.019-75%-0.015-80%-0.012-84%-0.010-87%
Return On Equity---0.213-0.053-75%-0.037-83%-0.029-86%-0.020-91%
Total Gains Per Share---0.433-0.108-75%-0.095-78%-0.076-83%-0.039-91%
Usd Book Value--29259869.00034450204.000-15%38615705.750-24%44042042.000-34%57835592.150-49%
Usd Book Value Change Per Share---0.433-0.108-75%-0.095-78%-0.076-83%-0.058-87%
Usd Book Value Per Share--2.0642.391-14%2.651-22%2.936-30%3.624-43%
Usd Dividend Per Share----0%-0%-0%0.019-100%
Usd Eps---0.444-0.099-78%-0.096-78%-0.073-83%-0.057-87%
Usd Free Cash Flow--953404.0001410192.500-32%1594896.500-40%1167334.050-18%629550.050+51%
Usd Free Cash Flow Per Share--0.0670.098-31%0.110-39%0.079-15%0.041+62%
Usd Free Cash Flow To Equity Per Share---0.038-0.031-19%0.073-151%-0.006-85%0.002-1905%
Usd Market Cap25375935.0000%25400035.05025556264.948-1%34800742.179-27%50030147.386-49%73371935.069-65%
Usd Price Per Share1.7900%1.7921.775+1%2.389-25%3.313-46%4.586-61%
Usd Profit---6291020.000-1568983.500-75%-1412509.750-78%-1115536.350-82%-876085.925-86%
Usd Revenue--9353066.0009888126.750-5%10502737.250-11%10126163.500-8%9696541.200-4%
Usd Total Gains Per Share---0.433-0.108-75%-0.095-78%-0.076-83%-0.039-91%
 EOD+4 -4MRQTTM+4 -30YOY+3 -315Y+3 -3110Y+8 -28

4.2. Fundamental Score

Let's check the fundamental score of Cumberland Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.008
Price to Book Ratio (EOD)Between0-10.867
Net Profit Margin (MRQ)Greater than0-0.673
Operating Margin (MRQ)Greater than0-0.223
Quick Ratio (MRQ)Greater than11.003
Current Ratio (MRQ)Greater than11.276
Debt to Asset Ratio (MRQ)Less than10.642
Debt to Equity Ratio (MRQ)Less than11.774
Return on Equity (MRQ)Greater than0.15-0.213
Return on Assets (MRQ)Greater than0.05-0.077
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cumberland Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.061
Ma 20Greater thanMa 501.901
Ma 50Greater thanMa 1001.991
Ma 100Greater thanMa 2001.897
OpenGreater thanClose1.750
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets81,776
Total Liabilities52,516
Total Stockholder Equity29,603
 As reported
Total Liabilities 52,516
Total Stockholder Equity+ 29,603
Total Assets = 81,776

Assets

Total Assets81,776
Total Current Assets35,714
Long-term Assets46,062
Total Current Assets
Cash And Cash Equivalents 18,322
Net Receivables 9,758
Inventory 4,609
Other Current Assets 3,025
Total Current Assets  (as reported)35,714
Total Current Assets  (calculated)35,714
+/-0
Long-term Assets
Property Plant Equipment 7,042
Goodwill 914
Intangible Assets 22,608
Long-term Assets Other 15,497
Long-term Assets  (as reported)46,062
Long-term Assets  (calculated)46,062
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities27,982
Long-term Liabilities24,534
Total Stockholder Equity29,603
Total Current Liabilities
Short-term Debt 348
Accounts payable 14,038
Other Current Liabilities 13,597
Total Current Liabilities  (as reported)27,982
Total Current Liabilities  (calculated)27,982
+/-0
Long-term Liabilities
Long term Debt 12,784
Capital Lease Obligations 5,644
Long-term Liabilities Other 274
Long-term Liabilities  (as reported)24,534
Long-term Liabilities  (calculated)18,702
+/- 5,831
Total Stockholder Equity
Common Stock47,092
Retained Earnings -17,488
Total Stockholder Equity (as reported)29,603
Total Stockholder Equity (calculated)29,603
+/-0
Other
Capital Stock47,092
Cash and Short Term Investments 18,322
Common Stock Shares Outstanding 14,164
Liabilities and Stockholders Equity 81,776
Net Debt 107
Net Invested Capital 42,388
Net Working Capital 7,732
Property Plant and Equipment Gross 9,280
Short Long Term Debt Total 18,428



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-31
> Total Assets 
0
0
0
26,481
26,854
28,124
28,125
28,919
30,631
28,647
30,372
31,119
30,986
33,348
101,656
103,724
98,690
96,702
89,910
92,054
91,575
94,581
96,079
95,518
94,568
95,381
96,934
98,594
98,278
95,466
91,911
87,614
91,106
93,469
93,904
95,405
92,190
92,917
92,059
91,919
89,206
87,889
91,074
93,405
91,862
87,803
90,351
93,232
91,095
90,445
87,432
112,694
114,618
107,546
103,766
104,549
97,419
97,523
96,010
96,463
93,348
88,851
87,571
84,460
96,697
92,518
91,425
92,925
89,469
89,375
87,751
81,776
81,77687,75189,37589,46992,92591,42592,51896,69784,46087,57188,85193,34896,46396,01097,52397,419104,549103,766107,546114,618112,69487,43290,44591,09593,23290,35187,80391,86293,40591,07487,88989,20691,91992,05992,91792,19095,40593,90493,46991,10687,61491,91195,46698,27898,59496,93495,38194,56895,51896,07994,58191,57592,05489,91096,70298,690103,724101,65633,34830,98631,11930,37228,64730,63128,91928,12528,12426,85426,481000
   > Total Current Assets 
0
0
0
12,643
12,814
13,766
13,558
14,789
16,588
14,962
17,016
17,710
17,621
19,911
91,553
93,174
88,344
86,661
79,897
81,039
81,102
84,344
85,878
87,308
86,283
86,257
86,792
87,232
86,020
82,441
78,270
68,680
69,266
70,632
70,150
70,815
67,545
68,201
67,722
67,112
64,923
63,992
66,963
65,545
63,542
63,293
66,083
68,685
66,823
66,648
63,626
74,865
57,966
51,932
49,398
50,163
44,737
45,755
48,894
49,970
49,383
46,681
47,216
45,688
45,342
43,748
49,015
45,870
43,811
43,674
41,770
35,714
35,71441,77043,67443,81145,87049,01543,74845,34245,68847,21646,68149,38349,97048,89445,75544,73750,16349,39851,93257,96674,86563,62666,64866,82368,68566,08363,29363,54265,54566,96363,99264,92367,11267,72268,20167,54570,81570,15070,63269,26668,68078,27082,44186,02087,23286,79286,25786,28387,30885,87884,34481,10281,03979,89786,66188,34493,17491,55319,91117,62117,71017,01614,96216,58814,78913,55813,76612,81412,643000
       Cash And Cash Equivalents 
0
0
0
6,255
8,999
9,478
9,165
10,815
11,912
10,317
11,163
11,830
10,072
12,531
79,541
78,702
73,753
71,495
65,518
65,894
65,959
69,832
71,075
70,599
55,644
52,273
50,802
54,349
51,210
49,665
46,011
40,869
39,048
39,051
39,644
39,866
39,045
38,941
38,316
38,203
36,441
35,837
35,546
34,510
34,974
34,616
42,019
45,413
35,263
35,907
38,259
27,939
24,609
20,951
26,978
28,213
27,027
27,374
26,647
24,754
24,923
25,670
25,843
27,041
17,267
18,217
19,542
19,758
16,386
18,249
18,508
18,322
18,32218,50818,24916,38619,75819,54218,21717,26727,04125,84325,67024,92324,75426,64727,37427,02728,21326,97820,95124,60927,93938,25935,90735,26345,41342,01934,61634,97434,51035,54635,83736,44138,20338,31638,94139,04539,86639,64439,05139,04840,86946,01149,66551,21054,34950,80252,27355,64470,59971,07569,83265,95965,89465,51871,49573,75378,70279,54112,53110,07211,83011,16310,31711,91210,8159,1659,4788,9996,255000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,002
18,245
18,559
16,686
18,959
19,514
19,163
14,020
13,532
14,826
14,634
14,841
13,865
14,137
14,439
14,564
14,866
14,565
14,600
15,622
15,479
14,356
8,055
4,672
15,610
14,803
9,534
8,291
9,667
9,480
2,266
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,2669,4809,6678,2919,53414,80315,6104,6728,05514,35615,47915,62214,60014,56514,86614,56414,43914,13713,86514,84114,63414,82613,53214,02019,16319,51418,95916,68618,55918,24516,002000000000000000000000000
       Net Receivables 
0
0
0
5,120
2,142
2,413
2,822
2,374
2,918
3,001
3,202
3,129
5,417
5,055
7,282
6,177
3,815
3,960
4,792
5,145
5,146
4,820
4,505
7,083
4,463
4,992
5,467
6,017
5,968
3,971
4,194
4,530
5,417
6,014
5,296
5,505
5,175
5,808
5,798
6,077
4,823
4,551
6,672
7,330
4,935
6,107
7,205
8,395
6,301
5,806
7,055
7,844
9,974
8,427
8,297
7,859
5,950
7,924
9,661
12,378
12,549
9,147
9,851
6,877
14,635
13,276
15,087
13,164
14,529
12,219
12,620
9,758
9,75812,62012,21914,52913,16415,08713,27614,6356,8779,8519,14712,54912,3789,6617,9245,9507,8598,2978,4279,9747,8447,0555,8066,3018,3957,2056,1074,9357,3306,6724,5514,8236,0775,7985,8085,1755,5055,2966,0145,4174,5304,1943,9715,9686,0175,4674,9924,4637,0834,5054,8205,1465,1454,7923,9603,8156,1777,2825,0555,4173,1293,2023,0012,9182,3742,8222,4132,1425,120000
       Other Current Assets 
0
0
0
48
75
51
42
651
584
696
852
989
786
1,217
3,042
3,472
3,370
3,238
1,941
2,316
2,175
2,239
3,424
3,851
4,169
3,430
4,452
1,671
3,892
3,198
3,466
826
3,847
3,744
4,445
1,351
4,826
4,520
4,963
1,469
4,719
4,117
5,161
2,711
2,508
2,659
2,946
3,467
2,987
2,786
2,352
2,964
2,456
2,425
1,992
2,757
2,319
2,085
1,778
2,200
1,900
1,758
1,259
3,340
3,561
2,835
3,739
3,549
2,715
2,278
1,971
3,025
3,0251,9712,2782,7153,5493,7392,8353,5613,3401,2591,7581,9002,2001,7782,0852,3192,7571,9922,4252,4562,9642,3522,7862,9873,4672,9462,6592,5082,7115,1614,1174,7191,4694,9634,5204,8261,3514,4453,7443,8478263,4663,1983,8921,6714,4523,4304,1693,8513,4242,2392,1752,3161,9413,2383,3703,4723,0421,21778698985269658465142517548000
   > Long-term Assets 
0
0
0
13,838
14,040
14,358
14,567
14,130
14,044
13,685
13,356
13,409
13,365
13,437
10,103
10,551
10,346
10,041
10,013
11,015
10,473
10,237
10,200
8,210
8,285
9,123
10,142
11,361
12,257
13,024
13,641
18,934
21,840
22,837
23,754
24,590
24,645
24,716
24,337
24,807
24,283
23,897
24,111
27,859
28,319
24,510
24,268
24,547
24,272
23,797
23,806
37,829
56,651
55,614
54,368
54,386
52,682
51,768
47,116
46,494
43,965
42,171
40,355
38,772
51,355
48,769
42,410
47,055
45,658
45,701
45,981
46,062
46,06245,98145,70145,65847,05542,41048,76951,35538,77240,35542,17143,96546,49447,11651,76852,68254,38654,36855,61456,65137,82923,80623,79724,27224,54724,26824,51028,31927,85924,11123,89724,28324,80724,33724,71624,64524,59023,75422,83721,84018,93413,64113,02412,25711,36110,1429,1238,2858,21010,20010,23710,47311,01510,01310,04110,34610,55110,10313,43713,36513,40913,35613,68514,04414,13014,56714,35814,04013,838000
       Property Plant Equipment 
0
0
0
366
379
371
412
460
471
467
450
432
425
505
597
918
949
959
1,140
1,220
1,197
1,196
1,199
1,119
1,055
1,100
1,121
1,189
1,153
1,056
975
881
809
727
731
651
685
569
542
536
558
506
483
464
538
495
475
529
567
550
539
771
744
737
744
3,708
3,428
3,134
2,871
2,602
2,319
2,029
1,776
1,467
1,170
951
1,505
5,502
5,274
7,216
7,089
7,042
7,0427,0897,2165,2745,5021,5059511,1701,4671,7762,0292,3192,6022,8713,1343,4283,7087447377447715395505675294754955384644835065585365425696856517317278098819751,0561,1531,1891,1211,1001,0551,1191,1991,1961,1971,2201,140959949918597505425432450467471460412371379366000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7,419,796
0
0
0
-97,798,977
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
784
882
882
882
882
882
882
882
882
882
882
882
882
1,933
1,933
1,933
914
914
914
914
914
9149149149149141,9331,9331,933882882882882882882882882882882882882784000000000000000000000000000-97,798,977000-7,419,7960000000000000000000
       Intangible Assets 
0
0
0
9,834
9,665
9,492
9,320
9,154
8,994
8,850
8,698
8,529
8,372
8,226
8,100
7,956
7,818
7,705
7,580
7,427,223
7,270
7,116
7,029
97,806,000
7,167
7,373
8,368
9,477
10,404
10,649
11,236
15,499
18,473
19,073
19,998
21,569
21,551
21,760
21,222
21,169
21,028
20,881
21,173
22,154
22,079
21,812
21,540
21,445
21,052
20,612
20,370
33,655
32,910
32,044
31,040
30,920
30,143
29,151
28,180
28,118
27,025
25,889
24,919
23,954
34,479
32,975
29,048
30,591
29,390
28,270
27,121
22,608
22,60827,12128,27029,39030,59129,04832,97534,47923,95424,91925,88927,02528,11828,18029,15130,14330,92031,04032,04432,91033,65520,37020,61221,05221,44521,54021,81222,07922,15421,17320,88121,02821,16921,22221,76021,55121,56919,99819,07318,47315,49911,23610,64910,4049,4778,3687,3737,16797,806,0007,0297,1167,2707,427,2237,5807,7057,8187,9568,1008,2268,3728,5298,6988,8508,9949,1549,3209,4929,6659,834000
       Other Assets 
0
0
0
0
0
0
0
13,670
0
0
0
12,977
12,940
12,932
9,506
9,632
9,397
9,082
8,873
9,795
9,276
9,041
9,001
7,091
7,230
8,024
9,021
10,173
11,105
11,969
12,666
18,053
21,031
22,110
23,023
23,939
23,960
24,147
23,795
24,271
23,725
23,391
23,628
27,395
27,782
24,015
23,793
24,018
2,653
2,634
2,897
18,368
18,627
18,690
18,655
18,876
18,229
18,601
15,183
17,801
13,739
13,372
12,779
12,468
13,773
12,911
9,924
10,048
0
9,302
0
0
009,302010,0489,92412,91113,77312,46812,77913,37213,73917,80115,18318,60118,22918,87618,65518,69018,62718,3682,8972,6342,65324,01823,79324,01527,78227,39523,62823,39123,72524,27123,79524,14723,96023,93923,02322,11021,03118,05312,66611,96911,10510,1739,0218,0247,2307,0919,0019,0419,2769,7958,8739,0829,3979,6329,50612,93212,94012,97700013,6700000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
1,209
0
0
0
579
0
0
0
1,211
0
0
0
3,120
3,537
0
0
87
87
87
87
87
44
44
44
22
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000224444448787878787003,5373,1200001,2110005790001,20900050000000000000000000000000000
> Total Liabilities 
0
0
0
15,355
14,631
13,584
12,285
12,172
12,396
9,102
9,270
13,564
12,534
13,469
30,995
31,503
25,005
23,400
15,284
14,339
13,189
13,156
12,622
12,683
12,720
12,167
13,602
13,027
13,248
12,592
10,979
8,322
12,146
12,736
13,019
14,652
12,845
14,215
14,515
15,099
13,887
13,514
16,652
20,284
19,649
21,309
25,433
29,311
30,221
30,774
29,487
57,123
59,427
53,858
52,059
53,464
47,576
49,112
48,166
49,590
46,470
41,043
40,925
41,858
55,904
53,313
52,934
56,951
53,420
52,538
52,095
52,516
52,51652,09552,53853,42056,95152,93453,31355,90441,85840,92541,04346,47049,59048,16649,11247,57653,46452,05953,85859,42757,12329,48730,77430,22129,31125,43321,30919,64920,28416,65213,51413,88715,09914,51514,21512,84514,65213,01912,73612,1468,32210,97912,59213,24813,02713,60212,16712,72012,68312,62213,15613,18914,33915,28423,40025,00531,50330,99513,46912,53413,5649,2709,10212,39612,17212,28513,58414,63115,355000
   > Total Current Liabilities 
0
0
0
8,698
8,383
8,555
7,846
8,119
8,759
8,712
8,880
7,606
6,359
7,937
13,559
18,624
15,459
15,427
9,913
9,228
8,753
10,728
7,453
6,600
6,160
7,132
8,658
8,055
8,236
6,095
5,412
7,546
11,350
11,863
12,155
13,749
11,895
11,548
11,874
12,412
11,138
8,895
11,686
14,792
14,071
12,981
15,798
17,695
16,290
16,814
15,518
27,804
27,999
22,317
21,053
24,150
19,373
22,664
23,938
25,667
22,848
18,647
17,945
19,279
24,557
24,252
25,954
28,580
25,707
26,959
27,328
27,982
27,98227,32826,95925,70728,58025,95424,25224,55719,27917,94518,64722,84825,66723,93822,66419,37324,15021,05322,31727,99927,80415,51816,81416,29017,69515,79812,98114,07114,79211,6868,89511,13812,41211,87411,54811,89513,74912,15511,86311,3507,5465,4126,0958,2368,0558,6587,1326,1606,6007,45310,7288,7539,2289,91315,42715,45918,62413,5597,9376,3597,6068,8808,7128,7598,1197,8468,5558,3838,698000
       Short-term Debt 
0
0
0
1,833
1,833
3,159
3,159
3,159
3,159
3,659
3,201
1,250
1,716
1,667
4,704
9,207
6,089
6,025
2,679
2,667
4,493
5,826
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,700
0
0
0
4,100
0
6,700
8,000
9,800
12,000
12,000
0
0
1,024
0
0
920
944
968
2,992
1,017
1,042
1,068
1,094
970
766
512
230
173
158
321
334
348
3483343211581732305127669701,0941,0681,0421,0172,992968944920001,0240012,00012,0009,8008,0006,70004,1000001,700000000000000000005,8264,4932,6672,6796,0256,0899,2074,7041,6671,7161,2503,2013,6593,1593,1593,1593,1591,8331,833000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,700
0
0
0
4,100
0
6,700
8,000
9,800
12,000
12,000
0
0
1,024
0
0
0
0
0
2,000
2,187
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002,1872,000000001,0240012,00012,0009,8008,0006,70004,1000001,700000000000000000000000000000000000000000
       Accounts payable 
0
0
0
3,373
3,199
3,308
2,269
1,921
3,287
2,922
3,044
3,257
2,296
2,420
5,798
5,633
6,814
5,993
3,416
2,125
2,171
2,302
3,280
1,514
2,304
2,936
4,228
2,791
3,427
3,094
2,272
2,036
4,725
4,220
3,205
3,243
3,371
4,110
4,127
2,877
4,067
3,667
6,658
8,037
7,270
6,412
7,922
8,980
8,519
10,066
8,447
11,093
9,292
9,540
8,227
9,994
8,248
10,830
10,834
13,396
10,466
8,963
9,233
9,641
11,448
10,592
11,511
10,819
11,222
10,912
10,818
14,038
14,03810,81810,91211,22210,81911,51110,59211,4489,6419,2338,96310,46613,39610,83410,8308,2489,9948,2279,5409,29211,0938,44710,0668,5198,9807,9226,4127,2708,0376,6583,6674,0672,8774,1274,1103,3713,2433,2054,2204,7252,0362,2723,0943,4272,7914,2282,9362,3041,5143,2802,3022,1712,1253,4165,9936,8145,6335,7982,4202,2963,2573,0442,9223,2871,9212,2693,3083,1993,373000
       Other Current Liabilities 
0
0
0
2,053
1,866
148
410
410
410
455
457
458
2,347
1,263
3,057
3,785
2,557
3,409
3,818
25
2,090
2,600
4,173
5,086
3,856
4,196
4,430
5,265
4,809
3,001
3,140
5,510
6,625
7,643
8,950
10,507
8,523
7,438
7,748
9,534
7,071
5,228
5,028
6,756
6,801
6,570
7,876
8,715
7,771
6,748
7,071
16,711
18,707
12,777
12,826
7,736
10,181
10,867
10,112
11,254
11,339
8,616
7,618
8,668
12,343
13,148
14,214
17,588
14,327
15,726
16,176
13,597
13,59716,17615,72614,32717,58814,21413,14812,3438,6687,6188,61611,33911,25410,11210,86710,1817,73612,82612,77718,70716,7117,0716,7487,7718,7157,8766,5706,8016,7565,0285,2287,0719,5347,7487,4388,52310,5078,9507,6436,6255,5103,1403,0014,8095,2654,4304,1963,8565,0864,1732,6002,090253,8183,4092,5573,7853,0571,2632,3474584574554104104101481,8662,053000
   > Long-term Liabilities 
0
0
0
6,657
6,248
5,029
4,440
4,053
3,637
390
390
5,958
6,175
5,532
17,437
12,879
9,545
7,973
5,371
5,111
4,436
2,428
5,168
6,083
6,560
5,035
4,944
4,972
5,012
6,498
5,567
776
796
873
863
903
951
2,667
2,641
2,687
2,749
4,619
4,966
5,491
5,579
8,328
9,635
11,616
13,931
13,960
13,969
29,319
31,428
31,540
31,006
29,314
28,203
26,448
24,228
23,922
23,623
22,396
22,979
22,579
31,346
29,061
26,979
28,371
27,713
25,579
24,767
24,534
24,53424,76725,57927,71328,37126,97929,06131,34622,57922,97922,39623,62323,92224,22826,44828,20329,31431,00631,54031,42829,31913,96913,96013,93111,6169,6358,3285,5795,4914,9664,6192,7492,6872,6412,6679519038638737967765,5676,4985,0124,9724,9445,0356,5606,0835,1682,4284,4365,1115,3717,9739,54512,87917,4375,5326,1755,9583903903,6374,0534,4405,0296,2486,657000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,826
4,576
4,860
5,110
4,360
4,360
4,360
4,360
5,860
4,860
0
0
0
0
0
0
1,700
1,700
1,700
1,700
3,500
3,700
4,100
4,100
6,700
8,000
9,800
12,000
12,000
12,000
20,000
20,000
20,000
20,000
18,500
18,500
0
0
15,000
0
0
0
0
0
0
0
0
0
0
0
0
00000000000015,0000018,50018,50020,00020,00020,00020,00012,00012,00012,0009,8008,0006,7004,1004,1003,7003,5001,7001,7001,7001,7000000004,8605,8604,3604,3604,3604,3605,1104,8604,5761,826000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
1,209
0
0
0
579
0
0
0
1,211
0
0
0
3,120
3,537
0
0
87
87
87
87
87
44
44
44
22
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000224444448787878787003,5373,1200001,2110005790001,20900050000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
3,137
0
0
0
382
386
159
181
185
182
209
212
618
610
602
592
578
1,450
675
584
613
652
638
707
776
796
873
864
903
950
967
941
987
1,049
1,119
1,266
1,392
1,479
1,628
1,635
1,815
1,931
1,960
1,969
9,319
8,823
9,038
8,690
8,737
7,872
7,868
7,904
7,863
7,833
7,884
7,749
7,489
11,324
10,061
9,279
7,585
0
6,954
0
0
006,95407,5859,27910,06111,3247,4897,7497,8847,8337,8637,9047,8687,8728,7378,6909,0388,8239,3191,9691,9601,9311,8151,6351,6281,4791,3921,2661,1191,0499879419679509038648737967767076386526135846751,4505785926026106182122091821851811593863820003,1370000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
645
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000064500000000000000000000000
> Total Stockholder Equity
0
0
0
11,126
12,223
14,540
15,840
16,746
18,235
19,545
21,102
17,555
18,464
19,900
70,687
72,254
73,728
73,352
74,683
77,778
78,458
81,507
83,547
82,929
81,951
83,325
83,450
85,696
85,173
83,026
81,098
79,468
79,148
80,933
81,103
80,761
79,372
78,741
77,590
76,888
75,402
74,471
74,530
73,248
72,359
66,657
65,095
64,120
61,086
59,907
58,202
55,845
55,432
54,061
51,733
51,123
49,890
48,481
47,929
46,991
47,017
47,953
46,822
42,814
41,023
39,463
38,764
36,266
36,361
37,159
35,992
29,603
29,60335,99237,15936,36136,26638,76439,46341,02342,81446,82247,95347,01746,99147,92948,48149,89051,12351,73354,06155,43255,84558,20259,90761,08664,12065,09566,65772,35973,24874,53074,47175,40276,88877,59078,74179,37280,76181,10380,93379,14879,46881,09883,02685,17385,69683,45083,32581,95182,92983,54781,50778,45877,77874,68373,35273,72872,25470,68719,90018,46417,55521,10219,54518,23516,74615,84014,54012,22311,126000
   Common Stock
0
0
0
0
0
0
0
17,319
0
0
0
13,500
13,191
630,000
1,930,000
1,930,000
100,000
68,199,165
68,521,470
70,778,874
70,737,856
71,609,043
71,802,068
-4,247,440,000
68,871,269
68,500,397
66,756,556
67,197
65,819
64,312
63,203
63,074
62,467
63,530
62,953
61,942
60,508
59,471
58,191
57,338
56,106
55,222
55,175
54,643
53,945
53,404
52,586
52,411
51,756
51,297
51,236
51,099
50,759
49,938
49,564
49,914
49,737
49,246
49,176
49,122
48,981
48,688
48,613
48,453
48,047
47,822
47,532
47,475
47,377
47,303
47,185
47,092
47,09247,18547,30347,37747,47547,53247,82248,04748,45348,61348,68848,98149,12249,17649,24649,73749,91449,56449,93850,75951,09951,23651,29751,75652,41152,58653,40453,94554,64355,17555,22256,10657,33858,19159,47160,50861,94262,95363,53062,46763,07463,20364,31265,81967,19766,756,55668,500,39768,871,269-4,247,440,00071,802,06871,609,04370,737,85670,778,87468,521,47068,199,165100,0001,930,0001,930,000630,00013,19113,50000017,3190000000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,898
11,745
12,657
13,080
14,824
16,694
18,499
19,354
18,715
17,895
16,395
16,681
17,403
18,149
18,818
18,865
19,271
19,399
19,550
19,297
19,248
19,355
18,605
18,413
13,253
12,510
11,709
9,330
8,609
6,966
4,746
4,672
4,123
2,169
1,208
153
-766
-1,247
-2,131
-1,964
-736
0
0
0
0
0
0
0
0
0
0
0000000000-736-1,964-2,131-1,247-7661531,2082,1694,1234,6724,7466,9668,6099,33011,70912,51013,25318,41318,60519,35519,24819,29719,55019,39919,27118,86518,81818,14917,40316,68116,39517,89518,71519,35418,49916,69414,82413,08012,65711,7459,898000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000-3,394-3,39400-3,125-3,12500-2,911-2,91100-2,700-2,70000-2,497-2,49700-2,240-2,24000-1,847-1,84700-1,441-1,44100-1,084-1,08400-726-72600-459-4590-632,6040-335000-276000-208000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
15,743
16,101
17,168
17,227
17,319
17,412
17,664
18,012
13,500
13,191
16,935
-1,863,566
-1,862,288
-31,138
-68,130,966
-68,452,949
-70,708,095
-70,667,118
-71,537,434
-71,730,266
4,247,510,272
-68,802,398
-68,431,897
-66,689,799
1,441
0
0
0
1,847
0
0
0
2,240
0
0
0
2,497
0
0
0
2,700
0
0
0
2,911
0
0
0
3,125
0
0
0
3,394
0
0
0
0
0
0
0
-212
0
0
0
0
0
0
0
0
00000000-21200000003,3940003,1250002,9110002,7000002,4970002,2400001,8470001,441-66,689,799-68,431,897-68,802,3984,247,510,272-71,730,266-71,537,434-70,667,118-70,708,095-68,452,949-68,130,966-31,138-1,862,288-1,863,56616,93513,19113,50018,01217,66417,41217,31917,22717,16816,10115,743000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue39,553
Cost of Revenue-11,003
Gross Profit28,55028,550
 
Operating Income (+$)
Gross Profit28,550
Operating Expense-35,031
Operating Income-6,481-6,481
 
Operating Expense (+$)
Research Development5,834
Selling General Administrative10,652
Selling And Marketing Expenses18,452
Operating Expense35,03134,938
 
Net Interest Income (+$)
Interest Income252
Interest Expense-668
Other Finance Cost-1
Net Interest Income-417
 
Pretax Income (+$)
Operating Income-6,481
Net Interest Income-417
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-6,285-6,678
EBIT - interestExpense = -7,149
-6,234
-5,611
Interest Expense668
Earnings Before Interest and Taxes (EBIT)-6,481-5,617
Earnings Before Interest and Taxes (EBITDA)-711
 
After tax Income (+$)
Income Before Tax-6,285
Tax Provision-69
Net Income From Continuing Ops-2,488-6,354
Net Income-6,279
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses46,034
Total Other Income/Expenses Net196417
 

Technical Analysis of Cumberland Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cumberland Pharmaceuticals Inc. The general trend of Cumberland Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cumberland Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cumberland Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.77 < 1.9 < 2.1.

The bearish price targets are: 1.69 > 1.6 > 1.6.

Tweet this
Cumberland Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cumberland Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cumberland Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cumberland Pharmaceuticals Inc. The current macd is -0.07637694.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cumberland Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cumberland Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cumberland Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cumberland Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCumberland Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cumberland Pharmaceuticals Inc. The current adx is 19.86.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cumberland Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cumberland Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cumberland Pharmaceuticals Inc. The current sar is 2.04954344.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cumberland Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cumberland Pharmaceuticals Inc. The current rsi is 42.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Cumberland Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCumberland Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cumberland Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cumberland Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cumberland Pharmaceuticals Inc Daily Stochastic Oscillator ChartCumberland Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cumberland Pharmaceuticals Inc. The current cci is -94.14128876.

Cumberland Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCumberland Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cumberland Pharmaceuticals Inc. The current cmo is -16.35097097.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cumberland Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCumberland Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cumberland Pharmaceuticals Inc. The current willr is -77.38392411.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cumberland Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cumberland Pharmaceuticals Inc Daily Williams %R ChartCumberland Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cumberland Pharmaceuticals Inc. The current atr is 0.11911234.

Cumberland Pharmaceuticals Inc Daily Average True Range (ATR) ChartCumberland Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cumberland Pharmaceuticals Inc. The current obv is 816,637.

Cumberland Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCumberland Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cumberland Pharmaceuticals Inc. The current mfi is 46.71.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cumberland Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCumberland Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cumberland Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Cumberland Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cumberland Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.061
Ma 20Greater thanMa 501.901
Ma 50Greater thanMa 1001.991
Ma 100Greater thanMa 2001.897
OpenGreater thanClose1.750
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cumberland Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Cumberland Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cumberland Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cumberland Pharmaceuticals Inc

I send you an email if I find something interesting about Cumberland Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cumberland Pharmaceuticals Inc.

Receive notifications about Cumberland Pharmaceuticals Inc in your mailbox!